Verve Therapeutics Price Target Cut to $29.00/Share From $30.00 by Canaccord Genuity
Express News | HC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target
Verve Therapeutics, Inc. (NASDAQ:VERV) Just Reported Earnings, And Analysts Cut Their Target Price
Express News | RBC Capital Maintains Outperform on Verve Therapeutics, Lowers Price Target to $20
Buy Rating Affirmed for Verve Therapeutics Amidst Clinical Progress and Strong Financials
Express News | Verve Therapeutics Inc : Canaccord Genuity Cuts Target Price to $29 From $30
RBC Capital Remains a Buy on Verve Therapeutics (VERV)
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), 4D Molecular Therapeutics (FDMT) and Carisma Therapeutics (CARM)
Express News | Verve Therapeutics Inc : RBC Cuts Target Price to $20 From $25
Verve Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Verve Therapeutics Inc: Cash Runway Into Late 2026
Verve Therapeutics 2Q Loss/Shr 59c >VERV
Express News | Verve Therapeutics Q2 EPS USD -0.59
Express News | Verve Therapeutics Q2 Collaboration Revenue USD 6.692 Million
Press Release: Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
RBC Cuts Price Target on Verve Therapeutics to $25 From $35, Keeps Outperform, Speculative Risk
Express News | Verve Therapeutics Inc : RBC Cuts Target Price to $25 From $35